83%
Decrease in Website Bounce Rate
Digital Biomarker Solutions
Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. The company’s leadership team came to Sagefrog wanting to build greater brand awareness, obtain more marketing qualified leads and sales qualified leads, increase sales conversions, and build its social media following. It also sought a refreshed brand identity, new website, HubSpot setup and onboarding, updated marketing materials, tactical marketing planning, and external marketing campaigns.
Sagefrog and Koneksa started with a complete Brand Strategy consisting of visioning, messaging, visual identity, and buyer personas and buyer’s journey. Sagefrog then built a strategic marketing plan to accomplish key objectives and designed and developed a custom responsive website as well as marketing materials, such as sell sheets, capabilities pitch decks, and stationery, to increase close rates. Sagefrog leveraged several tools to execute strategic marketing initiatives, launching multi-channel thought leadership campaigns for highly targeted audiences. PR and media support included writing press releases, conducting outreach, facilitating placement, and leading media buys. Digital marketing services contributed to increased brand awareness, and Sagefrog continued to assist Koneksa with pre-show, in-show, and post-show support for tradeshows, conferences, and webinars.
Decrease in Website Bounce Rate
Increase in LinkedIn Followers
Doubled Monthly Marketing Qualified Leads (MQLs)
Investment
Since the launch of its new brand, website, and integrated marketing program, Koneksa successfully elevated brand awareness and increased lead generation with Sagefrog as its trusted marketing partner. An impressive result of its new marketing initiatives was the opportunity to raise $61M in Series B and Series C financing, which earned the company a NASDAQ marquee feature celebrating the funding and a new CMO.